TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Pharmacy Times
AUGUST 13, 2025
4 “We are at an exciting moment in history,” said Daneshmand, who has been researching this novel treatment since 2016. Rates of serious treatment-related adverse events were 5.9%, 5.8%, 15.1%, and 3.6% in cohort 2, cohort 4, cohort 1, and cohort 3, respectively. No treatment-related deaths occurred. 3 REFERENCES 1.
Let's personalize your content